Vanessa Raymont
MBChB MSc MRCPsych
Associate Professor, R&D Director Oxford Health NHS Foundation Trust
- Honorary Senior Clinical Research Fellow, University of Edinburgh
- Honorary Consultant Psychiatrist
My clinical and research interests are in traumatic brain injury, and memory disorders and dementia, as well as clinical trials in cognitive impairment, having worked for over 25 years in clinical trials in the UK and US.
I am currently the Principal Investigator for the Synaptic Health in Neurodegeneration (SHINE) and Brains for Dementia Research (BDR) studies and multiple commercial early and late phase dementia clinical trials. I am Chief Investigator on the Deep and Frequent Phenotyping (DFP) study, a NHIR-funded study assessing the use of sertraline to prevent post-head injury depression (STOP-D) and am co-lead for the REAl world Dementia OUTcomes (READ-OUT) blood biomarker study that is part of the Alzheimer's Research UK Blood Biomarker Challenge. I am an associate director of Dementia Platforms UK, and workstream lead for the Trials Delivery Framework. I serve as a Commissioner for the Commission on Human Medicines and am co-Deputy Chair of the NIHR Dementia Translational Research Collaboration.
Recent publications
-
Blane J. et al, (2024)
-
Lennon MJ. et al, (2024), J Neurol Neurosurg Psychiatry
-
Raymont V., (2024), J Neurotrauma, 41
-
Gillis G. et al, (2024)
-
Low A. et al, (2024), JAMA Netw Open, 7
-
Jafarian A. et al, (2024), Hum Brain Mapp, 45
-
Creswell C. et al, (2024), Lancet Psychiatry, 11, 193 - 209
-
Karvandi E. et al, (2023), BMJ Open, 13
-
Artificial Intelligence for Dementia Prevention
NEWBY D. et al, (2023), Alzheimer's and Dementia
-
O'Donoghue MC. et al, (2023), BMJ Open, 13
-
Woods M. et al, (2023), Br J Hosp Med (Lond), 84, 1 - 3
-
Lennon MJ. et al, (2023), J Neurotrauma, 40, 1423 - 1435
-
Tari B. et al, (2023)
-
Natarajan A. et al, (2023), Syst Rev, 12
-
Tari B. et al, (2023)
-
Phiri P. et al, (2023)
-
Delanerolle G. et al, (2023)
-
Tari B. et al, (2023), Front Public Health, 11
-
Lanskey JH. et al, (2022), BMJ Open, 12
-
Taylor L. et al, (2022), Trials, 23
-
Manca R. et al, (2022), Acta Neuropsychiatr, 34, 276 - 281
-
Delanerolle G. et al, (2022), World J Psychiatry, 12, 1233 - 1254
-
Griffanti L. et al, (2022)
-
Taylor L. et al, (2022)
-
Phiri P. et al, (2022)
-
Delanerolle G. et al, (2022)
-
Raymont V. and Fleminger S., (2022), Cogn Neuropsychiatry, 27, 289 - 295
-
HISTORY OF INTIMATE PARTNER VIOLENCE IS ASSOCIATED WITH ADVERSE MENTAL HEALTH OUTCOMES IN MID-LIFE
Jenkins N. et al, (2022), JOURNAL OF NEUROTRAUMA, 39, A33 - A34
-
O’Donoghue MC. et al, (2022)
-
Delanerolle G. et al, (2022), World J Psychiatry, 12, 739 - 765
-
Delanerolle G. et al, (2022)
-
Natarajan A. et al, (2022)
-
Delanerolle G. et al, (2022)
-
Shetty A. et al, (2022)
-
Shetty A. et al, (2022), Front Digit Health, 4
-
Griffanti L. et al, (2022), Neuroimage Clin, 36
-
Manca R. et al, (2022), Front Psychiatry, 13
-
Pitt J. et al, (2021), Alzheimer's & Dementia, 17
-
Blane J. et al, (2021), Alzheimers Dement, 17 Suppl 11
-
Study protocol: SOcial LImitations Turn Up DEmentia (SOLITUDE)—Impact of COVID‐19 social isolation on patients’ cognition and mental health and on carers’ wellbeing
Manca R. et al, (2021), Alzheimer's & dementia : the journal of the Alzheimer's Association, 17
-
Manca R. et al, (2021), Alzheimers Dement, 17 Suppl 7
-
Lennon MJ. et al, (2021), J Alzheimers Dis
-
Delanerolle G. et al, (2021), EClinicalMedicine, 38
-
Burns DK. et al, (2021), The Lancet Neurology, 20, 537 - 547
-
Lanskey JH. et al, (2021)
-
Delanerolle G. et al, (2021)
-
Chau SWH. et al, (2021), BMC Public Health, 21
-
Phiri P. et al, (2021), EClinicalMedicine, 34
-
Delanerolle G. et al, (2021), World J Psychiatry, 11, 58 - 62
-
Baksh RA. et al, (2021), Psychol Aging, 36, 288 - 297
-
Delanerolle G. et al, (2021), British Journal of Neuroscience Nursing, 17, 13 - 16
-
Delanerolle G. et al, (2021), Womens Health (Lond), 17
-
Delanerolle G. et al, (2021), Womens Health (Lond), 17
-
Mendis SB. et al, (2021), Front Neurol, 12
-
Hapangama D. et al, (2020), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 30, A52 - A53
-
Calvin CM. et al, (2020), Alzheimers Res Ther, 12
-
Raymont V. and Thayanandan T., (2020), Minerva Med
-
Delanerolle G. et al, (2020), British Journal of Neuroscience Nursing, 16, 200 - 202
-
Terry GE. et al, (2020), PET and SPECT of Neurobiological Systems, 319 - 426
-
Jolly AE. et al, (2019), Neuroimage Clin, 24
-
Goel V. et al, (2019), J Cogn Neurosci, 1 - 14
-
Partnership in practice: an innovative Brain Health Centre
O'DONOGHUE M. et al, (2019)
-
Pardini M. et al, (2019), CNS Spectr, 1 - 8
-
Koychev I. et al, (2019), BMJ Open, 9
-
Eimontaite I. et al, (2018), Neuropsychologia
-
Mueller C. et al, (2018), International Journal of Therapy and Rehabilitation, 25, 107 - 119
-
Robert Brašić J. et al, (2018), Int J Phys Med Rehabil, 6
-
A preliminary report about the psychological effects of dopamine on people with the syndrome of Gilles de la Tourette. report about the psychological effects of dopamine on people with the syndrome of Gilles de la Tourette
Brasic J. et al, (2017), Journal of Nuclear Medicine, 58
-
Goel V. et al, (2017), Neuropsychologia, 99, 236 - 245
-
Greenan C. et al, (2016), Trials, 17
-
Huey ED. et al, (2016), JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 28, 104 - 111
-
Paradiso S. et al, (2016), JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 38, 887 - 899
-
Lewis JD. et al, (2015), BRAIN IMAGING AND BEHAVIOR, 9, 456 - 460
-
Davis RE. et al, (2015), Psychopharmacology (Berl), 232, 2863 - 2872
-
Knutson KM. et al, (2015), Journal of Neuropsychiatry and Clinical Neurosciences, 27, 193 - 198
-
Pardini M. et al, (2014), CNS SPECTRUMS, 19, 382 - 390
-
Wong D. et al, (2014), Neuropsychopharmacology, 39, 2272 - 2272
-
Schneider EB. et al, (2014), NEUROLOGY, 82, 1636 - 1642
-
Knutson KM. et al, (2014), HUMAN BRAIN MAPPING, 35, 943 - 953
-
Horti AG. et al, (2014), PET and SPECT of Neurobiological Systems, 249 - 319
-
Owen GS. et al, (2013), BRITISH JOURNAL OF PSYCHIATRY, 203, 461 - 467
-
Dal Monte O. et al, (2013), SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE, 8, 632 - 639
-
Wong DF. et al, (2013), Neuroimage, 75, 282 - 290
-
Glass L. et al, (2013), CEREBRAL CORTEX, 23, 1663 - 1672
-
Reduced dopamine blockade in the basal ganglia in obsessive-compulsive disorder
Brasic J. et al, (2013), JOURNAL OF NUCLEAR MEDICINE, 54
-
Raymont V. et al, (2013), New Journal of Chemistry, 37, 893 - 900
-
Rosenberg PB. et al, (2013), Am J Geriatr Psychiatry, 21, 272 - 278
-
Knutson KM. et al, (2013), NEUROPSYCHOLOGIA, 51, 686 - 694
-
Folio L. et al, (2013), MILITARY MEDICINE, 178, 338 - 345
-
Martin-Facklam M. et al, (2013), Neuropsychopharmacology, 38, 504 - 512
-
Waechter RL. et al, (2013), NEUROPSYCHOLOGIA, 51, 464 - 471
-
Dopamine release and serotonin interactions in Tourette's syndrome: new relations to obsessive compulsive disorder
Wong DF. et al, (2012), JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 32, S96 - S97
-
Effects of amphetamine-induced dopamine release and raclopride-induced dopamine blockade on psychiatric symptoms and tics of subjects with and without Gilles de la Tourette syndrome
Brasic JR. et al, (2012), JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 32, S92 - S92
-
Correlation of psychiatric symptoms and tics with amphetamine-induced dopamine release (DAR) in the striata of people with Gilles de la Tourette syndrome (TS) and obsessive-compulsive disorder (OCD)
Brasic J. et al, (2012), JOURNAL OF NUCLEAR MEDICINE, 53
-
Imaging biomarkers for the glycine transporter type 1
Wong D. et al, (2012), JOURNAL OF NUCLEAR MEDICINE, 53
-
Cannabinoid Receptor Subtype 1 (CB1) Distribution Correlates with Neuropsychiatric Ratings
Wong DF. et al, (2012), BIOLOGICAL PSYCHIATRY, 71, 258S - 258S
-
Brašić JR. et al, (2012), Synapse, 66, 352 - 368
-
Pardini M. et al, (2012), TRANSLATIONAL PSYCHIATRY, 2
-
Knutson KM. et al, (2012), COGNITIVE NEUROSCIENCE, 3, 131 - 138
-
Rostami E. et al, (2011), PLOS ONE, 6